Cross-tabulation of suspect peritoneal areas with near-infrared imaging according to BRCA status and neoadjuvant bevacizumab use
| Parameter | Near-infrared appearance* | Total | Near-infrared appearance* | Total | ||||
| Hypointense | Hyperintense | Hypointense | Hyperintense | |||||
| BRCA status | gBRCA1/2 wild-type | gBRCA1/2 mutant | ||||||
| Malignant†| No | Number | 10 | 5 | 15 | 4 | 4 | 8 |
| Percentage without malignancy | 66.7% | 33.3% | 100.0% | 50.0% | 50.0% | 100.0% | ||
| Yes | Number | 6 | 1 | 7 | 6 | 3 | 9 | |
| Percentage with malignancy | 85.7% | 14.3% | 100.0% | 66.7% | 33.3% | 100.0% | ||
| Use of neoadjuvant bevacizumab | Neoadjuvant bevacizumab - No | Neoadjuvant bevacizumab - Yes | ||||||
| Malignant†| No | Number | 11 | 8 | 19 | 3 | 1 | 4 |
| Percentage without malignancy | 57.9% | 42.1% | 100.0% | 75.0% | 25.0% | 100.0% | ||
| Yes | Number | 4 | 1 | 5 | 8 | 3 | 11 | |
| Percentage with malignancy | 80.0% | 20.0% | 100.0% | 72.7% | 27.3% | 100.0% | ||
*Samples under white light not deemed clinically suspicious grouped by near-infrared status.
†Pathological confirmation of malignancy for samples identified based on the near-infrared protocol.